What are the recommended treatment options for a 62-year-old woman with early relapsing-onset multiple sclerosis?

Treatment Options for Early MS in a 62-Year-Old Female

For a 62-year-old woman with early relapsing-onset multiple sclerosis, high-efficacy disease-modifying therapies (DMTs) should be initiated as first-line treatment, with ocrelizumab being the preferred option based on the strongest evidence for early intervention and long-term outcomes.

Rationale for High-Efficacy DMT as First-Line Treatment

The paradigm has shifted from stepped care to early escalation strategies in MS management 1. Starting with high-efficacy DMTs from disease onset provides superior long-term outcomes compared to escalating from lower-efficacy agents 2. This is particularly critical because disability and brain volume loss that accumulate while on lower-efficacy treatments cannot be recovered even after switching to more effective therapies 2.

Age-Specific Considerations

While your patient is 62 years old, age alone should not preclude aggressive treatment if she has early, active disease. However, several factors require careful assessment 3:

• Immunosenescence: Reduced immune resilience affects both infection risk and vaccine response
• Comorbidities: Screen for cardiovascular disease, diabetes, osteoporosis, and malignancy
• Polypharmacy: Review all medications for potential drug interactions
• Infection risk: Baseline infections are more consequential in older adults

Specific Treatment Recommendations

First-Line Options (in order of preference):

1. Ocrelizumab (Anti-CD20 Monoclonal Antibody)

• Strongest evidence for early intervention: 9-year data shows 78.7% of treatment-naïve patients had no confirmed disability progression 2
• Achieves NEDA-3 (no evidence of disease activity) in 72.5% of early patients versus 43.8% with interferon 2
• Reduces annualized relapse rate by 46-47% compared to interferon 4
• Administration: IV infusion every 6 months
• Key monitoring: Screen for hepatitis B, tuberculosis; monitor for infections and infusion reactions 4

2. Ofatumumab (Anti-CD20 Monoclonal Antibody)

• Similar mechanism to ocrelizumab with subcutaneous self-administration
• May be preferred if IV access is problematic
• Monthly subcutaneous injections after loading doses

3. Natalizumab

• Highly effective but requires JC virus antibody testing
• Reserved for JC virus-negative patients or those accepting PML risk
• Monthly IV infusions

4. Cladribine

• Oral immune reconstitution therapy
• Two treatment courses over 2 years, then potentially treatment-free
• Reduces long-term immunosuppression burden—advantageous in older adults 3
• Requires lymphocyte monitoring

Alternative Options:

Moderate-Efficacy DMTs (generally NOT recommended as first-line in early active disease):

• Interferons, glatiramer acetate, teriflunomide, fumarates
• Reduce relapse rates by only 29-44% 4
• Critical caveat: Starting with these agents results in irreversible disability and brain volume loss before escalation 2

Treatment Algorithm

Step 1: Confirm Diagnosis

• Apply 2024 McDonald criteria 5
• MRI with gadolinium showing dissemination in space and time
• Consider CSF analysis for kappa free light chains if diagnosis uncertain 5
• Rule out red flags: progressive course from onset, atypical MRI patterns, systemic symptoms suggesting alternative diagnoses 6, 7

Step 2: Assess Disease Activity

• Relapse frequency and severity
• MRI lesion burden and gadolinium-enhancing lesions
• Disability level (EDSS score)
• In early relapsing-remitting MS, 80% of new lesions show gadolinium enhancement 8

Step 3: Pre-Treatment Evaluation (Age-Specific)

• Complete blood count, liver/renal function
• Hepatitis B/C, HIV, tuberculosis screening
• JC virus antibody status
• Vaccination status (complete before starting immunosuppressive therapy) 3
• Cardiovascular risk assessment
• Bone density screening
• Malignancy screening appropriate for age

Step 4: Initiate Treatment

• Start ocrelizumab unless contraindicated
• If ocrelizumab contraindicated: consider ofatumumab, natalizumab (if JC virus-negative), or cladribine
• Avoid starting with moderate-efficacy DMTs in active disease

Step 5: Monitoring

• MRI at 6-12 months, then annually
• Clinical assessment every 3-6 months
• Monitor for infections, particularly respiratory and urinary tract
• Annual influenza and pneumococcal vaccination (timing relative to infusions matters)

Special Consideration: AHSCT

Autologous hematopoietic stem cell transplantation (AHSCT) is now considered standard of care for highly active MS refractory to high-efficacy DMTs 1. However:

• Not first-line therapy at age 62
• Consider only if ocrelizumab or other high-efficacy DMT fails after meaningful treatment period
• Younger age and fewer prior DMTs predict better AHSCT outcomes 1
• Requires specialized center evaluation

Critical Pitfalls to Avoid

1. Do not start with moderate-efficacy DMTs in early active disease—this results in irreversible disability accumulation 2
2. Do not delay treatment waiting to see if disease is "benign"—early inflammatory activity predicts worse outcomes
3. Do not undertreat based on age alone—early active disease requires aggressive management regardless of age
4. Do not forget age-appropriate screening before immunosuppression—infections and malignancies are more consequential in older adults 3
5. Do not skip vaccination before starting therapy—immune response diminishes after treatment initiation

Acute Relapse Management

If presenting with acute relapse:

• Methylprednisolone 1000 mg IV daily for 3-5 days 6, 7
• Initiate DMT immediately after completing steroids
• Do not wait for complete recovery to start DMT

The evidence strongly supports immediate initiation of high-efficacy DMT in your 62-year-old patient with early relapsing MS, with ocrelizumab as the preferred first-line agent, provided appropriate pre-treatment screening and age-specific comorbidity assessment are completed.